iBio, Inc.

**Signal Note: EcoR1 Capital Initiates $4.3M Position in iBio** EcoR1's entry into IBIO suggests conviction in the company's pipeline scaling, likely driven by iBio's plant-based manufacturing platform and near-term clinical catalysts (IBIO's COVID vaccine candidates and contract manufacturing agreements). The $4.3M position from a growth-stage crossover investor typically signals confidence in revenue inflection or upcoming data readouts within 12-24 months, though position size remains modest relative to market cap and warrants monitoring for follow-on insider activity to confirm thesis strength.